Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors

NCT07539610 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

B-Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia/Lymphoma

Interventions

BIOLOGICAL: Sup19 CAR-T

Sponsor

Institute of Hematology & Blood Diseases Hospital, China